uses its proprietary Deep Learning and Deep Sequencing workflow...
to extensively and rapidly mine antibody repertoires in order to deliver highly specific antibody leads with improved binding characteristics, manufacturability properties, and an increased probability of clinical success.
Our lead time is significantly accelerated by our proprietary mammalian display method, allowing us to deliver a diverse panel of candidate antibodies within 3 month.
Our Partner's targets are screened against 10^9 possible genetic variants, and can be titrated down to only 100 antibody sequences against requirements of affinity, specificity, and manufacturability.
We aim to beat the industry standard lead time by half, delivering sequence data within 3 months.